MedTrace Logo

Study to Gather Information How Often Venous Thromboembolism Occurs in Prostate Cancer Patients in Sweden and How This Condition is Treated With Blood Thinners

NCT03965741 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 97765

Last updated 2021-11-30

No results posted yet for this study

Summary

Patients with cancer are at a significantly increased risk of experiencing a venous thromboembolism (VTE). VTE is defined by a blood clot in the leg or lower extremity (deep vein thrombosis) or a blood clot in the lung (pulmonary embolism) and is a leading cause of condition of being diseased and death among cancer patients. The goal of the study is to gather information how often venous thromboembolism (VTE) occurs in prostate cancer patients in Sweden and how this condition is treated with blood thinners.

Conditions

  • Venous Thromboembolism (VTE)

Interventions

DRUG

Rivaroxaban (Xarelto, BAY59-7939)

Follow clinical administration

DRUG

Apixaban(Eliquis)

Follow clinical administration

DRUG

Pradaxa (Dabigatran etexilate)

Follow clinical administration

Sponsors & Collaborators

  • Janssen Research & Development, LLC

    collaborator INDUSTRY

  • Bayer

    lead INDUSTRY

Eligibility

Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-30
Primary Completion
2020-11-30
Completion
2020-11-30

Countries

  • Sweden

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03965741 on ClinicalTrials.gov